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Congenital heart disease (CHD) is one of the most common groups of birth defects1, 
contributing to a major portion of mortality in early childhood and consuming large amounts 
of healthcare and family resources. They have a birth prevalence of 6–8/1000 live births, 
excluding late recognized defects such as BAV which has a population frequency of 1–2%1.
Genetic epidemiology studies and reports of multiple recurrences of CHDs within families 
demonstrate a strong genetic component. Familial clustering of CHDs is particularly 
apparent when grouped by developmental mechanism2. A recent large study using hundreds 
of these multiplex families confirmed the concept of grouping CHD by developmental 
mechanism, and supporting animal data suggests these groupings are due to perturbations of 
genetic networks important in cardiogenesis3. Indeed, of all risk factors for CHD, a family 
history of CHD has the highest relative risk even over maternal diabetes or twinning4. More 
formal segregation analyses have confirmed the strong genetic component, also noting the 
inheritance pattern is likely complex and oligogenic2.
This evidence for the genetic basis of CHD spurred investigators to search for responsible 
loci and genes. A few early successes occurred using the traditional genetic approach of 
linkage, identifying pathogenic variants in NKX2-55, NOTCH16, and GATA47 among 
multiplex families with CHDs. Unfortunately, further successes have been scarce, with the 
exception of CHDs occurring as part of a syndrome (such as the RASopathies). Genome-
wide association studies (GWAS) for specific groups of CHD have added a few more loci, 
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but with limited replications in a second study8, 9. Copy number variant (CNV) studies have 
identified novel genomic disorders in as many as 20% of syndromic cases, a few percent of 
nonsyndromic CHDs, including identification of individuals with multiple CNVs10–12. The 
advent of next-generation sequencing technology raised hopes that this bottleneck in gene 
discovery would be resolved. Early studies appeared exciting, with the identification of 
chromatin remodeling genes in CHD cases13. Unfortunately it appears at least some 
individuals may have had unrecognized or undefined syndromes that include CHDs, rather 
than an isolated CHD. Subsequent studies have found de novo changes in only 1–2% of 
those cases14, thus the cause remains elusive for isolated CHD. These studies also highlight 
the significant difficulty in case ascertainment, the need for careful (and longitudinal) 
phenotyping, and the challenges of variant interpretation.
While the causes of syndromes that include CHD as part of the phenotype have been 
answered more successfully, an interesting question has arisen: Why does only a portion of 
individuals with the syndrome have a CHD?Conversely, individuals with specific syndromes 
offer a unique opportunity to study a population with susceptibility to CHDs. This topic was 
highlighted in our previous editorial on Modifying Mendel15 in which Li et al. used a 
trisomy 21 (Down syndrome) mouse (Ts65dn) in an attempt to answer the question of CHD 
risk using this sensitized model16. Their work implicated Creld1 and Gata4 in mouse, 
supported by data from human T21 subjects, providing one of the first studies on 
modification of a major susceptibility locus (in this case an extra chromosome 21) in the 
causation of CHD.
The article by Guo et al.17 in this issue is among the first to use an unbiased approach to 
identifying a modifier locus for CHD in humans. Using GWAS in individuals with a deletion 
of 22q11.2 (22q11DS), the authors combined bioinformatics of the human locus with 
additional studies in mice to narrow down to a potential candidate gene. 22q11DS is the 
most common genomic disorder that causes CHD. Individuals may have characteristic 
dysmorphic features, velopalatal abnormalities (cleft or insufficiency), hypocalcemia, 
immunodeficiency, and a variety of neurodevelopmental disorders. Most individuals have 
CHD related to second heart field developmental anomalies, including truncus arteriosus, 
interrupted aortic arch type B, and most commonly, tetralogy of Fallot (TOF).
Dr. Morrow’s group was able to assemble an impressive cohort of nearly 1500 carefully 
phenotyped individuals with 22q11DS. Over 1200 samples were SNP genotyped on an 
Affymetrix 6.0 platform. The analysis was careful and thorough, including proper quality 
control and accounting for possible biases from population stratification. Comparing 
22q11DS subjects with TOF (n=326) to 22q11DS subjects with normal cardiac anatomy 
(n=566) in the cohort, they identified a locus on 5q14.3 with multiple SNPs (genotyped and 
imputed) exceeding the threshold for genome-wide significance. The highest associated SNP 
was rs12519770 (p=2.98×10–8) with an odds ratio of 1.69. This locus was further narrowed 
to a ~100kb interval within an intron of GPRC78 using additional whole genome sequencing 
of just under 400 22q11DS subjects. Bioinformatic analysis of chromatin confirmation (Hi-
C) showed that this region lay in a topological associated domain of 2.3 Mb size, containing 
six genes: GPR98, MEF2C, CETN3, MBLAC2, POLR3G, and LYSMD3. Expression 
studies in mouse were performed using in-situ hybridization, and only Mef2c demonstrated 
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expression in cardiac progenitor cells. MEF2C is a very biologically plausible candidate 
gene, as it is an important transcription factor during cardiogenesis, acting in a network that 
regulates second heart field development.
Several weaknesses in this study are important to note, despite the huge effort by this group. 
Relatively speaking, this study is small by GWAS standards, thus it was powered to only be 
able to identify loci associated with large effect sizes. They did not have a second, 
replication cohort; however, assembling this size of initial cohort at all is a striking 
accomplishment. Finally, although the authors performed appropriate analyses to control for 
population stratification, inclusion of a variety of populations (European, Hispanic, African 
American, Asian) does create some concern for false positive results. Further work will also 
be required to identify whether the SNPs in the intron of GPR78 are themselves functional 
or tag an as yet unidentified variant, and to determine the mechanistic basis by which the 
functional variants modify or cause CHDs in 22q11DS. Whether this study data can be 
generalized to other second heart field malformations not associated with 22q11DS will be 
interesting to see. While further validation of these data will be important, the results 
provide initial data on a potential modifier that causes CHD in 22q11DS individuals.
The previous study using T21 as a susceptibility group and known mouse CHD genes 
provided proof of principle that variant burden threshold influences disease penetrance. This 
current study by Dr. Morrow’s group advances the field in an important way by 
demonstrating that an unbiased approach in a human susceptibility population is able to 
identify a modifier locus. Other syndromes with CHD as part of the phenotype, such as 
Noonan syndrome and other RASopathies, are additional candidates for this type of study.
Identifying major susceptibility loci, let alone modifiers, remains a challenge for isolated 
CHDs. Here, several approaches are promising. First, multiplex families are also a 
susceptibility population. Rates of identifying major susceptibility loci are much higher, 
with identification of pathogenic variants in 25–30% of families, compared to 1–2% of 
sporadic cases14, 18. Genome approaches in multiplex families also offer an unbiased screen 
for finding multiple loci. Second, brute force animal models, such as using mouse forward 
genetic screens (inducing mutation followed by high throughput phenotypic screening), can 
find not only major susceptibility loci but also digenic inheritance or modifier loci. This has 
already been successfully accomplished by Dr. Cecilia Lo’s group, who found two genes 
causing hypoplastic left heart syndrome (HLHS) in a forward mouse screen followed by 
identification of variants in these genes in human subjects with HLHS19.
Many difficulties lie ahead. Phenotyping remains a problem not only for anatomic features 
of a specific individual, but also for the correct grouping of distinct, but related, 
malformations. Statistical modeling has yet to be successful given the small numbers of 
subjects with CHDs that can be collected. Even large groups, such as the Pediatric 
Cardiovascular Genetics Consortium, would be unable to collect the thousands of samples 
necessary to identify significant results in rare variant analyses by current statistical 
methods. Methods for multiplex families for narrowing the list of potential variants in 
oligogenic inheritance models are lacking. In addition, studying multiple variants in multiple 
genes in animal models is slow, laborious and expensive. Newer techniques, such as use of 
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CRISPR/Cas9 to more quickly create animal models, and use of fruit fly to rapidly and 
cheaply study variants in multiple loci via multiple crosses, may offer some hope20.
The genetics of CHD appears to be more complex than previously thought. The field will 
need to move away from simple Mendelian genetic models to those with multiple loci, 
possibly a major locus with one or more modifiers, or multiple loci acting together. This 
concept is not unique to the CHD genetics field. Other cardiovascular genetic diseases have 
well established complex patterns of inheritance that are already altering how patients with 
these diseases are diagnosed and managed in clinical practice. Arrhythmogenic right 
ventricular cardiomyopathy, where up to 10% of individuals have two disease causing 
variants, and long QT syndrome where two pathogenic variants lead to more severe 
phenotype that includes deafness, are two examples.
Dr. Morrow’s group shows that modifiers of Mendelian CHD traits can be found. These 
methods should become part of future study designs in CHD genetics.
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